New drug trial aims to tackle dual threat of heart failure and diabetes

NCT ID NCT07303556

Summary

This study is testing if a newer diabetes medication called tirzepatide can improve heart function and overall health in people who have both chronic heart failure and type 2 diabetes. 120 adults in Kazakhstan will receive the drug and be closely monitored for 40 weeks. Researchers will also check if a person's genetics affects how well they respond to the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • PI "National Laboratory Astana", Nazarbayev University

    Astana, Kazakhstan, 010000, Kazakhstan

Conditions

Explore the condition pages connected to this study.